Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 32620549.
- Also identified by DOI 10.1136/gutjnl-2020-321829 and PMC identifier 7456726.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The COVID-19 pandemic has led to an exponential increase in SARS-CoV-2 infections and associated deaths, and represents a significant challenge to healthcare professionals and facilities. Individual countries have taken several prevention and containment actions to control the spread of infection, including measures to guarantee safety of both healthcare professionals and patients who are at increased risk of infection from COVID-19. Faecal microbiota transplantation (FMT) has a well-established role in the treatment of <i>Clostridioides difficile</i> infection. In the time of the pandemic, FMT centres and stool banks are required to adopt a workflow that continues to ensure reliable patient access to FMT while maintaining safety and quality of procedures. In this position paper, based on the best available evidence, worldwide FMT experts provide guidance on issues relating to the impact of COVID-19 on FMT, including patient selection, donor recruitment and selection, stool manufacturing, FMT procedures, patient follow-up and research activities.
Medical subject headings
- Clostridium Infections
- Coronavirus Infections
- Donor Selection
- Fecal Microbiota Transplantation
- Gastroenterology
- Pandemics
- Patient Selection
- Pneumonia, Viral